Antibody-drug  	Antibody-drug  	 JJ	B-NP
conjugate  	conjugate  	 JJ	O
technology  	technology  	 NN	B-NP
development  	development  	 NN	I-NP
for  	for  	 IN	I-NP
hematologic  	hematologic  	 JJ	I-NP
disorders  	disorders  	 NNS	I-NP
Antibody-drug  	Antibody-drug  	 JJ	I-NP
conjugates  	conjugates  	 NNS	O
( 	( 	 -LRB-	O
ADCs 	ADCs 	 NNP	B-NP
)  	)  	 -RRB-	O
combine  	combine  	 VB	O
cytotoxic  	cytotoxic  	 JJ	B-NP
chemotherapy  	chemotherapy  	 NN	I-NP
and  	and  	 CC	O
antibody  	antibody  	 NN	B-NP
specificity 	specificity 	 NN	I-NP
.  	.  	 .	O
There  	There  	 EX	O
are  	are  	 VBP	O
4  	4  	 CD	O
components  	components  	 NNS	O
of  	of  	 IN	O
ADC  	ADC  	 NNP	B-NP
technology 	technology 	 NN	I-NP
:  	:  	 :	O
the  	the  	 DT	O
cancer 	cancer 	 NN	O
,  	,  	 ,	O
or  	or  	 CC	O
target 	target 	 NN	O
,  	,  	 ,	O
antigen 	antigen 	 NN	B-NP
;  	;  	 :	O
the  	the  	 DT	O
antibody  	antibody  	 NN	B-NP
to  	to  	 TO	O
that  	that  	 DT	O
target 	target 	 NN	O
;  	;  	 :	O
the  	the  	 DT	O
linker  	linker  	 NN	B-NP
that  	that  	 WDT	O
connects  	connects  	 VBZ	O
the  	the  	 DT	O
drug  	drug  	 NN	O
to  	to  	 TO	O
the  	the  	 DT	O
antibody 	antibody 	 NN	B-NP
;  	;  	 :	O
and  	and  	 CC	O
the  	the  	 DT	O
drug  	drug  	 NN	O
itself 	itself 	 PRP	O
.  	.  	 .	O
The  	The  	 DT	O
antibody  	antibody  	 NN	B-NP
directs  	directs  	 VBZ	O
the  	the  	 DT	O
cytotoxic  	cytotoxic  	 JJ	B-NP
agent  	agent  	 NN	I-NP
to  	to  	 TO	O
the  	the  	 DT	O
tumor  	tumor  	 NN	B-NP
cell 	cell 	 NN	I-NP
,  	,  	 ,	O
thereby  	thereby  	 RB	O
diminishing  	diminishing  	 VBG	O
the  	the  	 DT	O
side  	side  	 NN	B-NP
effect  	effect  	 NN	I-NP
profile  	profile  	 NN	I-NP
of  	of  	 IN	I-NP
the  	the  	 DT	I-NP
cytotoxic  	cytotoxic  	 JJ	I-NP
agent  	agent  	 NN	I-NP
and  	and  	 CC	O
enabling  	enabling  	 VBG	B-NP
delivery  	delivery  	 NN	I-NP
of  	of  	 IN	O
a  	a  	 DT	O
more  	more  	 RBR	O
potent  	potent  	 JJ	O
therapeutic  	therapeutic  	 NN	O
because  	because  	 IN	O
of  	of  	 IN	O
the  	the  	 DT	O
ability  	ability  	 NN	B-NP
to  	to  	 TO	O
control  	control  	 VB	O
the  	the  	 DT	O
target  	target  	 NN	O
and  	and  	 CC	O
the  	the  	 DT	O
side  	side  	 NN	B-NP
effects 	effects 	 NNS	I-NP
.  	.  	 .	O
ADC  	ADC  	 NNP	B-NP
technology  	technology  	 NN	I-NP
has  	has  	 VBZ	O
vastly  	vastly  	 RB	O
improved  	improved  	 VBN	O
within  	within  	 IN	O
the  	the  	 DT	O
last  	last  	 JJ	O
several  	several  	 JJ	O
years 	years 	 NNS	O
.  	.  	 .	O
In  	In  	 IN	O
early  	early  	 JJ	O
ADCs 	ADCs 	 NN	B-NP
,  	,  	 ,	O
the  	the  	 DT	O
linkers  	linkers  	 NN	B-NP
were  	were  	 VBD	O
too  	too  	 RB	O
labile 	labile 	 JJ	O
,  	,  	 ,	O
which  	which  	 WDT	O
led  	led  	 VBD	O
to  	to  	 TO	O
the  	the  	 DT	O
release  	release  	 NN	O
of  	of  	 IN	O
free  	free  	 JJ	O
drug  	drug  	 NN	O
in  	in  	 IN	O
the  	the  	 DT	O
circulation  	circulation  	 NN	O
and  	and  	 CC	O
consequent  	consequent  	 JJ	O
off-target  	off-target  	 JJ	B-NP
toxicity 	toxicity 	 NN	I-NP
.  	.  	 .	O
In  	In  	 IN	O
the  	the  	 DT	O
current  	current  	 JJ	O
generation  	generation  	 NN	O
of  	of  	 IN	O
ADCs 	ADCs 	 NNP	B-NP
,  	,  	 ,	O
the  	the  	 DT	O
linkers  	linkers  	 NNS	B-NP
are  	are  	 VBP	O
more  	more  	 RBR	O
stable 	stable 	 JJ	O
,  	,  	 ,	O
and  	and  	 CC	O
the  	the  	 DT	O
cytotoxic  	cytotoxic  	 JJ	B-NP
agents  	agents  	 NNS	I-NP
are  	are  	 VBP	O
significantly  	significantly  	 RB	O
more  	more  	 RBR	O
potent 	potent 	 JJ	O
.  	.  	 .	O
ADCs  	ADCs  	 NNS	B-NP
have  	have  	 VBP	O
been  	been  	 VBN	O
developed  	developed  	 VBN	O
against  	against  	 IN	O
a  	a  	 DT	O
variety  	variety  	 NN	O
of  	of  	 IN	O
antigens  	antigens  	 NN	B-NP
and  	and  	 CC	O
receptors 	receptors 	 NNS	B-NP
,  	,  	 ,	O
including  	including  	 VBG	B-NP
CD19 	CD19 	 NNP	I-NP
,  	,  	 ,	O
CD22 	CD22 	 NNP	B-NP
,  	,  	 ,	O
and  	and  	 CC	O
CD30 	CD30 	 NNP	B-NP
,  	,  	 ,	O
and  	and  	 CC	O
have  	have  	 VBP	O
been  	been  	 VBN	O
linked  	linked  	 VBN	O
to  	to  	 TO	O
multiple  	multiple  	 JJ	O
different  	different  	 JJ	O
cytotoxic  	cytotoxic  	 JJ	B-NP
agents 	agents 	 NNS	I-NP
,  	,  	 ,	O
including  	including  	 VBG	B-NP
calicheamicin  	calicheamicin  	 NNS	I-NP
and  	and  	 CC	O
maytansinoid  	maytansinoid  	 JJ	B-NP
derivatives 	derivatives 	 NNS	I-NP
.  	.  	 .	O
The  	The  	 DT	O
ADC  	ADC  	 NNP	B-NP
brentuximab  	brentuximab  	 NN	I-NP
vedotin  	vedotin  	 NNS	I-NP
was  	was  	 VBD	O
recently  	recently  	 RB	O
approved  	approved  	 VBN	O
by  	by  	 IN	O
the  	the  	 DT	O
US  	US  	 NNP	O
Food  	Food  	 NNP	O
and  	and  	 CC	O
Drug  	Drug  	 NNP	B-NP
Administration  	Administration  	 NNP	I-NP
for  	for  	 IN	O
the  	the  	 DT	O
treatment  	treatment  	 NN	O
of  	of  	 IN	O
patients  	patients  	 NNS	O
with  	with  	 IN	O
Hodgkin  	Hodgkin  	 NNP	B-NP
lymphoma  	lymphoma  	 NN	I-NP
after  	after  	 IN	O
failure  	failure  	 NN	O
of  	of  	 IN	O
autologous  	autologous  	 JJ	B-NP
stem  	stem  	 NN	I-NP
cell  	cell  	 NN	I-NP
transplant  	transplant  	 NN	I-NP
or  	or  	 CC	O
at  	at  	 IN	O
least  	least  	 JJS	O
2  	2  	 CD	O
prior  	prior  	 JJ	O
multiagent  	multiagent  	 JJ	B-NP
chemotherapy  	chemotherapy  	 JJ	I-NP
regimens 	regimens 	 NN	I-NP
,  	,  	 ,	O
and  	and  	 CC	O
the  	the  	 DT	O
treatment  	treatment  	 NN	O
of  	of  	 IN	O
patients  	patients  	 NNS	O
with  	with  	 IN	O
systemic  	systemic  	 JJ	B-NP
anaplastic  	anaplastic  	 JJ	I-NP
large  	large  	 JJ	I-NP
cell  	cell  	 NN	I-NP
lymphoma  	lymphoma  	 NN	I-NP
after  	after  	 IN	O
failure  	failure  	 NN	O
of  	of  	 IN	O
at  	at  	 IN	O
least  	least  	 JJS	O
1  	1  	 CD	O
prior  	prior  	 JJ	O
multiagent  	multiagent  	 JJ	B-NP
chemotherapy  	chemotherapy  	 JJ	I-NP
regimen 	regimen 	 NN	I-NP
.  	.  	 .	O
Other  	Other  	 JJ	B-NP
ADCs  	ADCs  	 NN	I-NP
in  	in  	 IN	O
clinical  	clinical  	 JJ	B-NP
trials  	trials  	 NNS	I-NP
for  	for  	 IN	I-NP
hematologic  	hematologic  	 JJ	I-NP
disorders  	disorders  	 NNS	I-NP
include  	include  	 VBP	O
inotuzumab  	inotuzumab  	 JJ	B-NP
ozogamicin 	ozogamicin 	 NN	I-NP
,  	,  	 ,	O
SAR3419 	SAR3419 	 NNP	O
,  	,  	 ,	O
and  	and  	 CC	O
gemtuzumab  	gemtuzumab  	 JJ	B-NP
ozogamicin 	ozogamicin 	 NN	I-NP
.  	.  	 .	O
